Allgemeine Grundlagen der Tumorbiologie in der
                    Viszeralchirurgie

G. Emons; M. Ghadimi; M. Grade

doi:10.1055/s-0032-1328590

Zentralblatt für Chirurgie - Zeitschrift für Allgemeine, Viszeral-, Thorax- und Gefäßchirurgie, Inhaltsverzeichnis

Zentralbl Chir 2015; 140(1): 74-82
DOI: 10.1055/s-0032-1328590

Übersicht

Georg Thieme Verlag KG Stuttgart · New York

Allgemeine Grundlagen der Tumorbiologie in der Viszeralchirurgie

General Principles of Tumour Biology in Visceral Surgery

G. Emons

Allgemein-, Viszeral- und Kinderchirurgie, Universitätsmedizin Göttingen, Deutschland

,

M. Ghadimi

Allgemein-, Viszeral- und Kinderchirurgie, Universitätsmedizin Göttingen, Deutschland

,

M. Grade

Allgemein-, Viszeral- und Kinderchirurgie, Universitätsmedizin Göttingen, Deutschland

› Institutsangaben

Abstract

Zusammenfassung

In den letzten Jahren konnten auf dem Gebiet der onkologischen Grundlagenforschung große Fortschritte erzielt werden. Insbesondere wurden die Entstehung und die charakteristischen Eigenschaften von Tumorzellen zunehmend entschlüsselt. Das Verständnis dieser molekularen Grundlagen ist entscheidend für die zukünftige Entwicklung und Etablierung neuer, zielgerichteter Therapiestrategien sowie deren Integration in den klinischen Alltag (personalisierte Medizin). Zudem spielt die Tumorgenetik insbesondere auf dem Gebiet der hereditären Krebssyndrome eine entscheidende Rolle sowohl in der Diagnostik als auch für die Therapieplanung. Ziel dieser Übersichtsarbeit ist es, allgemeine Grundlagen der Tumorgenetik aus Sicht des Viszeralchirurgen aufzuzeigen und zu erläutern, auch wenn aufgrund der Komplexität der Materie eine allumfassende Zusammenstellung nicht möglich ist.

Abstract

Within the last decade, there has been a tremendous progress in understanding the molecular basis of cancer. In particular, the development and the characteristic features of cancer cells are being increasingly understood. The understanding of these molecular characteristics is mandatory for the development of novel, targeted therapeutic strategies and their integration into clinical practice. In addition, tumour genetics play a critically important role for hereditary cancer syndromes, with respect to both diagnostics and clinical decision-making. The aim of this review is to highlight general principles of tumour genetics from a visceral surgeonʼs point of view, although a comprehensive summary of all aspects would be beyond the scope of this article due to the complexity of the topic.

Schlüsselwörter

Viszeralchirurgie - Tumorbiologie - molekulare Onkologie - personalisierte Medizin - hereditäre Krebssyndrome

Key words

visceral surgery - tumour biology - molecular oncology - personalised medicine - hereditary cancer syndromes

Volltext

Referenzen

Literatur
1 Blay JY, Le Cesne A, Cassier PA et al. Gastrointestinal stromal tumors (GIST): a rare entity, a tumor model for personalized therapy, and yet ten different molecular subtypes. Discov Med 2012; 13: 357-367
2 Ballestrero A, Garuti A, Cirmena G et al. Patient-tailored treatments with anti-EGFR monoclonal antibodies in advanced colorectal cancer: KRAS and beyond. Curr Cancer Drug Targets 2012; 12: 316-328
3 Aretz S. The differential diagnosis and surveillance of hereditary gastrointestinal polyposis syndromes. Dtsch Arztebl Int 2010; 107: 163-173
4 Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70
5 Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674
6 Hayman MJ, Enrietto PJ. Cell transformation by the epidermal growth factor receptor and v-erbB. Cancer Cells 1991; 3: 302-307
7 Garnett MJ, Marais R. Guilty as charged: B-RAF is a human oncogene. Cancer Cell 2004; 6: 313-319
8 Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol 2012; 13: 283-296
9 Cho KR, Vogelstein B. Genetic alterations in the adenoma–carcinoma sequence. Cancer 1992; 70: 1727-1731
10 Fearon ER. Molecular genetics of colorectal cancer. Annu Rev Pathol 2011; 6: 479-507
11 Vousden KH, Prives C. Blinded by the light: the growing complexity of p 53. Cell 2009; 137: 413-431
12 Partanen JI, Nieminen AI, Klefstrom J. 3D view to tumor suppression: Lkb1, polarity and the arrest of oncogenic c-Myc. Cell Cycle 2009; 8: 716-724
13 Okada T, Lopez-Lago M, Giancotti FG. Merlin/NF-2 mediates contact inhibition of growth by suppressing recruitment of Rac to the plasma membrane. J Cell Biol 2005; 171: 361-371
14 Cotter TG. Apoptosis and cancer: the genesis of a research field. Nat Rev Cancer 2009; 9: 501-507
15 Chan SR, Blackburn EH. Telomeres and telomerase. Philos Trans R Soc Lond B Biol Sci 2004; 359: 109-121
16 Aubert G, Lansdorp PM. Telomeres and aging. Physiol Rev 2008; 88: 557-579
17 Blackburn EH. Telomeres and telomerase: the means to the end (Nobel lecture). Angew Chem Int Ed Engl 2010; 49: 7405-7421
18 Artandi SE, DePinho RA. Telomeres and telomerase in cancer. Carcinogenesis 2010; 31: 9-18
19 Risau W. Mechanisms of angiogenesis. Nature 1997; 386: 671-674
20 Folkman J, Hanahan D. Switch to the angiogenic phenotype during tumorigenesis. Princess Takamatsu Symp 1991; 22: 339-347
21 Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307: 58-62
22 Hay ED. The mesenchymal cell, its role in the embryo, and the remarkable signaling mechanisms that create it. Dev Dyn 2005; 233: 706-720
23 Brabletz T, Jung A, Spaderna S. Opinion: migrating cancer stem cells – an integrated concept of malignant tumour progression. Nat Rev Cancer 2005; 5: 744-749
24 Brabletz T, Hlubek F, Spaderna S et al. Invasion and metastasis in colorectal cancer: epithelial-mesenchymal transition, mesenchymal-epithelial transition, stem cells and beta-catenin. Cells Tissues Organs 2005; 179: 56-65
25 Day DW, Morson BC. The adenoma-carcinoma sequence. Major Probl Pathol 1978; 10: 58-71
26 Vogelstein B, Fearon ER, Hamilton SR et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988; 319: 525-532
27 Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-767
28 Sjoblom T, Jones S et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006; 314: 268-274
29 Wood LD, Parsons DW et al. The genomic landscapes of human breast and colorectal cancers. Science 2007; 318: 1108-1113
30 The Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487: 330-337
31 Seshagiri S, Stawiski EW et al. Recurrent R-spondin fusions in colon cancer. Nature 2012; 488: 660-664
32 Polakis P. The many ways of Wnt in cancer. Curr Opin Genet Dev 2007; 17: 45-51
33 Hajra KM, Fearon ER. Cadherin and catenin alterations in human cancer. Genes Chromosomes Cancer 2002; 34: 255-268
34 Moss SF, Liu TC, Petrotos A et al. Inward growth of colonic adenomatous polyps. Gastroenterology 1996; 111: 1425-1432
35 Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer 2003; 3: 459-465
36 Seiden-Long IM, Brown KR, Shih W et al. Transcriptional targets of hepatocyte growth factor signaling and Ki-ras oncogene activation in colorectal cancer. Oncogene 2006; 25: 91-102
37 Drabsch Y, Dijke P. TGF-beta signalling and its role in cancer progression and metastasis. Cancer Metastasis Rev 2012; 31: 553-568
38 Baker SJ, Preisinger AC, Jessup JM et al. p 53 gene mutations occur in combination with 17 p allelic deletions as late events in colorectal tumorigenesis. Cancer Res 1990; 50: 7717-7722
39 Schneider R, Schneider C, Kloor M et al. Lynch syndrome: clinical, pathological, and genetic insights. Langenbecks Arch Surg 2012; 397: 513-525
40 Umar A, Boland CR, Terdiman JP et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004; 96: 261-268
41 Jasperson KW, Tuohy TM, Neklason DW et al. Hereditary and familial colon cancer. Gastroenterology 2010; 138: 2044-2058
42 Claes K, Dahan K, Tejpar S et al. The genetics of familial adenomatous polyposis (FAP) and MutYH-associated polyposis (MAP). Acta Gastroenterol Belg 2011; 74: 421-426
43 Wolthuis AM, Leonard D, Kartheuser A et al. Different surgical strategies in the treatment of familial adenomatous polyposis: whatʼs the role of the ileorectal anastomosis?. Acta Gastroenterol Belg 2011; 74: 435-437
44 Glascock MJ, Carty SE. Multiple endocrine neoplasia type 1: fresh perspective on clinical features and penetrance. Surg Oncol 2002; 11: 143-150
45 Ivo D, Corset L, Desbourdes L et al. Menin controls the concentration of retinoblastoma protein. Cell Cycle 2011; 10: 166-168
46 Trump D, Farren B, Wooding C et al. Clinical studies of multiple endocrine neoplasia type 1 (MEN1). QJM 1996; 89: 653-669
47 Akerstrom G, Stalberg P. Surgical management of MEN-1 and − 2: state of the art. Surg Clin North Am 2009; 89: 1047-1068
48 Thakker RV. Multiple endocrine neoplasia type 1 (MEN1). Best Pract Res Clin Endocrinol Metab 2010; 24: 355-370
49 Thakker RV, Newey PJ, Walls GV et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab 2012; 97: 2990-3011
50 Moline J, Eng C. Multiple endocrine neoplasia type 2: an overview. Genet Med 2011; 13: 755-764
51 Arighi E, Borrello MG, Sariola H. RET tyrosine kinase signaling in development and cancer. Cytokine Growth Factor Rev 2005; 16: 441-467
52 Wohllk N, Schweizer H, Erlic Z et al. Multiple endocrine neoplasia type 2. Best Pract Res Clin Endocrinol Metab 2011; 24: 371-387
53 Waguespack SG, Rich TA, Perrier ND et al. Management of medullary thyroid carcinoma and MEN2 syndromes in childhood. Nat Rev Endocrinol 2011; 7: 596-607
54 Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730-737
55 Simons BD, Clevers H. Stem cell self-renewal in intestinal crypt. Exp Cell Res 2011; 317: 2719-2724
56 Dalerba P, Dylla SJ, Park IK et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A 2007; 104: 10158-10163
57 Gupta PB, Onder TT, Jiang G et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009; 138: 645-659
58 Adams JM, Strasser A. Is tumor growth sustained by rare cancer stem cells or dominant clones?. Cancer Res 2008; 68: 4018-4021
59 Schepers AG, Snippert HJ, Stange DE et al. Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas. Science 2012; 337: 730-735
60 Driessens G, Beck B, Caauwe A et al. Defining the mode of tumour growth by clonal analysis. Nature 2012; 488: 527-530
61 Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993; 75: 843-854
62 He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004; 5: 522-531
63 Esquela-Kerscher A, Slack FJ. Oncomirs – microRNAs with a role in cancer. Nat Rev Cancer 2006; 6: 259-269
64 Gaedcke J, Grade M, Camps J et al. The Rectal Cancer microRNAome – microRNA Expression in Rectal Cancer and Matched Normal Mucosa. Clin Cancer Res 2012; 18: 4919-4930
65 Goel A, Boland CR. Epigenetics of Colorectal Cancer. Gastroenterology 2012; 143: 1442-1460
66 Caplen NJ, Mousses S. Short interfering RNA (siRNA)-mediated RNA interference (RNAi) in human cells. Ann N Y Acad Sci 2003; 1002: 56-62
67 Grade M, Hummon AB, Camps J et al. A genomic strategy for the functional validation of colorectal cancer genes identifies potential therapeutic targets. Int J Cancer 2011; 128: 1069-1079
68 Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012; 21: 309-322
69 Tammela T, Alitalo K. Lymphangiogenesis: Molecular mechanisms and future promise. Cell 2010; 140: 460-476
70 Gaengel K, Genove G, Armulik A et al. Endothelial-mural cell signaling in vascular development and angiogenesis. Arterioscler Thromb Vasc Biol 2009; 29: 630-638
71 Pietras K, Ostman A. Hallmarks of cancer: interactions with the tumor stroma. Exp Cell Res 2010; 316: 1324-1331
72 Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell 2010; 141: 39-51
73 Lander ES. Initial impact of the sequencing of the human genome. Nature 2011; 470: 187-197
74 Gonzaga-Jauregui C, Lupski JR, Gibbs RA. Human genome sequencing in health and disease. Annu Rev Med 2012; 63: 35-61
75 Torkamani A, Scott-Van Zeeland AA, Topol EJ et al. Annotating individual human genomes. Genomics 2011; 98: 233-241
76 Hunter DJ, Khoury MJ, Drazen JM. Letting the genome out of the bottle – will we get our wish?. N Engl J Med 2008; 358: 105-107
77 Prainsack B, Wolinsky H. Direct-to-consumer genome testing: opportunities for pharmacogenomics research?. Pharmacogenomics 2010; 11: 651-655
78 Khoury MJ, McBride CM, Schully SD et al. The Scientific Foundation for personal genomics: recommendations from a National Institutes of Health-Centers for Disease Control and Prevention multidisciplinary workshop. Genet Med 2009; 11: 559-567
79 Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012; 489: 519-525
80 Gaedcke J, Liersch T, Hess C et al. [Rectal cancer: current status of multimodal therapy – when and how]?. Zentralbl Chir 2011; 136: 334-342
81 Ghadimi BM, Grade M, Difilippantonio MJ et al. Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. J Clin Oncol 2005; 23: 1826-1838
82 Gaedcke J, Grade M, Jung K et al. KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy. Radiother Oncol 2010; 94: 76-81
83 Spitzner M, Emons G, Kramer F et al. A gene expression signature for chemoradiosensitivity of colorectal cancer cells. Int J Radiat Oncol Biol Phys 2012; 78: 1184-1192
84 Jo P, Jung K, Grade M et al. CpG island methylator phenotype infers a poor disease-free survival in locally advanced rectal cancer. Surgery 2012; 151: 564-570
85 Kendziorra E, Ahlborn K, Spitzner M et al. Silencing of the Wnt transcription factor TCF4 sensitizes colorectal cancer cells to (chemo-) radiotherapy. Carcinogenesis 2011; 32: 1824-1831
86 Grade M, Wolff HA, Gaedcke J et al. The molecular basis of chemoradiosensitivity in rectal cancer: implications for personalized therapies. Langenbecks Arch Surg 2012; 397: 543-555
87 Heining C, von Kalle C. Translationale Onkologie – Effiziente Umsetzung onkologischer Grundlagenforschung. Zentralbl Chir 2012; 137: 1-3